Guggenheim analyst Shahriar Pourreza maintains Spire (NYSE:SR) with a Neutral and raises the price target from $61 to $63.
What’s Going On With GSK Stock Today?
GSK settles U.S. Zantac lawsuit, avoiding trial. Confidential settlements reinforce commitment to legal efficiency.